UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.

FORM ~~8-K~~8K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~January~~May 131, 2013

Date of Report (Date of earliest event reported)

~~Nano~~NMI ~~Mask~~Health, Inc.

(Exact name of registrant as specified in its charter)

Nevada	000-27421	87-0561647
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Nano Mask, Inc.

(Former name or former address if changed since last report)


Nevada	00027421	870561647
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)


50 West Liberty Street, Suite 880, Reno, Nevada	89501
(Address of principal executive offices)	(Zip Code)

209-275-9270

Registrant's telephone number, including area code

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Nano Mask, Inc. (the “Company”) has ~~appointed~~accepted ~~Dr.~~the ~~Hassan~~resignation ~~Bennani to its board~~ of ~~directors.~~Director ~~Dr.~~Hassan Bennani iseffective ~~the~~May ~~co-founder and CEO of KellBenx~~31, ~~Incorporated,~~2013. aMr. ~~closely~~Bennani ~~held~~resigned ~~Long~~for ~~Island,~~personal NYreasons ~~based~~not ~~biotechnology~~as ~~company focused on women's healthcare, concentrating on~~ the ~~development~~result of aany ~~patented~~disagreement ~~breakthrough~~with ~~non-invasive~~the ~~prenatal~~Company ~~diagnostic~~on ~~(NIPD)~~any ~~for~~matter ~~analyzing~~relating ~~genetic disorders and a patent pending breakthrough test~~ to ~~determine~~the ~~a woman'~~Company’s ~~risk~~operations, ofpolicies ~~preterm~~or ~~delivery~~practices.

~~Dr.~~Item ~~Bennani was previously the head of business development at Lenetix, a women's health focused lab acquired by Bio-Reference Laboratories~~8. ~~Prior~~01 toOther ~~that, Dr. Bennani was a Vice President of Sales and Marketing for Adeza Biomedical Corporation, which was acquired by Hologic.~~ Events

~~There~~The isCompany noannounced ~~arrangement~~that orits ~~understanding~~name ~~with~~change ~~any~~from ~~other~~Nano ~~person~~Mask, ~~pursuant~~Inc. to ~~which~~NMI DrHealth, Inc. ~~Bennani~~and ~~was~~1-for-10 ~~appointed.~~reverse Drstock split is effective as of June 5, 2013. As ~~Bennani~~previously ~~will~~disclosed bein ~~entitled~~the toInformation ~~compensation~~Statement asfiled on April 9, 2013, the Company's Board of Directors, upon receiving written shareholder consent in lieu of a ~~non-employee~~shareholders’ ~~director~~meeting, ~~pursuant~~elected to effect a reverse stock split of the Company’'s ~~current~~common ~~non~~stock at a ratio of 1-~~employee~~for-10 ~~director~~and ~~compensation~~to ~~policy~~change atits anname ~~annual~~from ~~rate~~Nano ofMask, ~~$15~~Inc. to NMI Health,~~000~~ Inc. ~~The~~to ~~board~~better ~~has~~reflect ~~not~~the ~~yet~~nature ~~determined~~of aits ~~committee~~products ~~assignment~~and ~~for~~current ~~Dr.~~business ~~Bennani~~focus.

AAs ~~press~~of ~~release~~June ~~announcing~~5, 2013, every ten shares of the ~~board~~Company's ~~appointment~~issued isand ~~attached~~outstanding tocommon ~~this~~stock ~~filing~~have been converted into one issued and outstanding share of common stock. The par value per share remains unchanged at $ 0.001 per share, as anhas ~~exhibit~~the number of shares of common stock authorized, which remains at 100,000,000. The number of shares of the Company's issued and outstanding common stock has been reduced to approximately 9,869,544. Any fractional shares have been rounded up to the next whole share. In addition, the reverse stock split will effect a proportionate adjustment to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options and warrants to purchase or acquire shares of the Company's common stock.

~~Item 9.01 Financial Statements and Exhibits~~SIGNATURES

ExPursuant 99to –the ~~Press~~requirements ~~release~~of ~~dated~~the ~~January~~Securities 24Exchange Act of 1934, ~~2013~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~SIGNATURES~~DATED: June 11, 2013

~~Pursuant~~NMI toHealth, ~~the~~Inc. ~~requirements~~(formerly ofNano ~~the Securities Exchange Act of 1934~~Mask, ~~the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized~~Inc.)

~~DATED~~By: /S/ ~~January~~Edward ~~24,~~J. ~~2013~~Suydam

~~Nano~~Edward ~~Mask~~Suydam, ~~Inc.~~CEO and President

By: /S/ Edward J. Suydam

Edward Suydam, CEO and President

Filing Compare · NMI Health, Inc.